Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury

American Journal of Physiology - Renal Physiology

Volumn 285, Issue 3 54-3, 2003, Pages

  Okusa, Mark D ^a,c   Ye, Hong ^a   Huang, Liping ^a   Sigismund, Laura ^a   Macdonald, Timothy ^b   Lynch, Kevin R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Acute renal failure; Kidney; Oleoyl methoxy phosphothionate; VPC 12249

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID 1 RECEPTOR; LYSOPHOSPHATIDIC ACID 2 RECEPTOR; LYSOPHOSPHATIDIC ACID 3 RECEPTOR; MESSENGER RNA; OLEOYLMETHOXYPHOSPHOTHIONATE; RECEPTOR BLOCKING AGENT; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; VPC 12249;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; HYPOTHESIS; KIDNEY CORTEX; KIDNEY FAILURE; KIDNEY ISCHEMIA; KIDNEY MEDULLA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REPERFUSION INJURY;

EID: 0041508881     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00023.2003     Document Type: Article

References (32)

1. Bradley PP, Priebat DA, Christensen RD, and Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with enzyme marker. J Invest Dermatol 78: 206-209, 1982.
2. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, and Lynch KR. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457, 2002.
3. Chien KR, Abrams J, Serroni A, Martin JT, and Farber JL. Accelerated phospholipid degradation and associated membrane dysfunction in irreversible, ischemic liver cell injury. J Biol Chem 253: 4809-4817, 1978.
4. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, Pyne S, and Tigyi G. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54: 265-269, 2002.
5. Dixon RJ and Brunskill NJ. Lysophosphatidic acid-induced proliferation in opossum kidney proximal tubular cells: role of PI 3-kinase and ERK. Kidney Int 56: 2064-2075, 1999.
6. Fueller M, Wang de A, Tigyi G, and Siess W. Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate. Cell Signal 15: 367-375, 2003.
7. Fukushima N, Ishii I, Contos JJ, Weiner JA, and Chun J. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol 41: 507-534, 2001.
8. Goetzl EJ and An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J 12: 1589-1598, 1998.
9. Graler MH and Goetzl EJ. Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim Biophys Acta 1582: 168-174, 2002.
10. 3 receptor. J Biol Chem 278: 11962-11969, 2003.
11. Hashimoto T, Nakano Y, Yamashita M, Fang YI, Ohata H, and Momose K. Role of Rho-associated protein kinase and histamine in lysophosphatidic acid-induced airway hyperresponsiveness in guinea pigs. Jpn J Pharmacol 88: 256-261, 2002.
12. Hashizume H, Chen M, Ma H, Hara A, Yazawa K, Akahira M, Xiao CY, and Abiko Y. A new approach to the development of anti-ischemic drugs: protective drugs against cell injury induced by lysophosphatidylcholine. Life Sci 62: 1695-1699, 1998.
13. Hashizume H, Hoque AN, Magishi K, Hara A, and Abiko Y. A new approach to the development of anti-ischemic drugs. Substances that counteract the deleterious effect of lysophosphatidylcholine on the heart. Jpn Heart J 38: 11-25, 1997.
14. 3 receptor antagonist. Mol Pharmacol 60: 1173-1180, 2001.
15. Hooks SB, Santos WL, Im DS, Heise CE, Macdonald TL, and Lynch KR. Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J Biol Chem 276: 4611-4621, 2001.
16. Im DS, Heise CE, Harding MA, George SR, O'Dowd BF, Theodorescu D, and Lynch KR. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol Pharmacol 57: 753-759, 2000.
17. Lee H, Liao JJ, Graeler M, Huang MC, and Goetzl EJ. Lysophospholipid regulation of mononuclear phagocytes. Biochim Biophys Acta 1582: 175-177, 2002.
18. Levine JS, Koh JS, Triaca V, and Lieberthal W. Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am J Physiol Renal Physiol 273: F575-F585, 1997.
19. Li CY, Lam KW, and Yam LT. Esterases in human leukocytes. J Histochem Cytochem 21: 1-12, 1973.
20. Matthys E, Patel Y, Kreisberg J, Stewart JH, and Venkatachalam M. Lipid alterations induced by renal ischemia: pathogenic factor in membrane damage. Kidney Int 26: 153-161, 1984.
21. Moolenaar WH. Lysophosphatidic acid signalling. Curr Opin Cell Biol 7: 203-210, 1995.
22. Morahan PS, Edelson PJ, and Gass K. Changes in macrophage ectoenzymes associated with anti-tumor activity. J Immunol 125: 1312-1317, 1980.
23. Okusa MD. The inflammatory cascade in acute ischemic renal failure. Nephron 90: 133-138, 2002.
24. Okusa MD, Huang L, Momose-Hotokezaka A, Huynh LP, and Mangrum AJ. Regulation of adenylyl cyclase by G protein-coupled receptors in polarized renal epithelial cells. Am J Physiol Renal Physiol 273: F883-F891, 1997.
25. Okusa MD, Linden J, Huang L, Rieger JM, Macdonald TL, and Huynh LP. A2a-Adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal Physiol 279: F809-F818, 2000.
26. Rehncrona S, Westerberg E, Akesson B, and Siesjo BK. Brain cortical fatty acids and phospholipids during and following complete and severe incomplete ischemia. J Neurochem 38: 84-93, 1982.
27. Sautin YY, Crawford JM, and Svetlov SI. Enhancement of survival by LPA via Erk1/Erk2 and PI 3-kinase/Akt pathways in a murine hepatocyte cell line. Am J Physiol Cell Physiol 281: C2010-C2019, 2001.
28. Sobel BE, Corr PB, Robison AK, Goldstein RA, Witkowski FX, and Klein MS. Accumulation of lysophosphoglycerides with arrhythmogenic properties in ischemic myocardium. J Clin Invest 62: 546-553, 1978.
29. Stefan C, Gijsbers R, Stalmans W, and Bollen M. Differential regulation of the expression of nucleotide pyrophosphatases/ phosphodiesterases in rat liver. Biochim Biophys Acta 1450: 45-52, 1999.
30. Thadhani R, Pascual M, and Bonventre JV. Acute renal failure. N Engl J Med 334: 1448-1460, 1996.
31. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, and Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158: 227-233, 2002.
32. Van Corven EJ, Groenink A, Jalink K, Eichholtz T, and Moolenaar WH. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59: 45-54, 1989.